{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:34Z","timestamp":1792800154789,"version":"4.5.0"},"reference-count":95,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI32313"],"award-info":[{"award-number":["R01AI32313"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hantaviruses, members of the order Bunyavirales, family Hantaviridae, have a world-wide distribution and are responsible for greater than 150,000 cases of disease per year. The spectrum of disease associated with hantavirus infection include hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) also known as hantavirus cardiopulmonary syndrome (HCPS). There are currently no FDA-approved vaccines or treatments for these hantavirus diseases. This review provides a summary of the status of vaccine and antiviral treatment efforts including those tested in animal models or human clinical trials.<\/jats:p>","DOI":"10.3390\/v11070610","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T11:13:18Z","timestamp":1562238798000},"page":"610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Progress on the Prevention and Treatment of Hantavirus Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4377-0710","authenticated-orcid":false,"given":"Rebecca L.","family":"Brocato","sequence":"first","affiliation":[{"name":"Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W.","family":"Hooper","sequence":"additional","affiliation":[{"name":"Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"ref_1","first-page":"1244","article-title":"Bunyaviridae","volume":"Volume 1","author":"Knipe","year":"2013","journal-title":"Fields Virology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Avsic-Zupanc, T., Saksida, A., and Korva, M. (2019). Hantavirus infections. Clin. Microbiol. Infect.","DOI":"10.1111\/1469-0691.12291"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/JVI.00725-11","article-title":"Migration of norway rats resulted in the worldwide distribution of seoul hantavirus today","volume":"86","author":"Lin","year":"2012","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.antiviral.2007.10.012","article-title":"Treatment of hantavirus pulmonary syndrome","volume":"78","author":"Jonsson","year":"2008","journal-title":"Antiviral Res."},{"key":"ref_5","first-page":"1629","article-title":"Person-to-person household and nosocomial transmission of andes hantavirus, southern chile, 2011","volume":"20","author":"Calvo","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"467059","DOI":"10.1155\/2012\/467059","article-title":"The role of the endothelium in hps pathogenesis and potential therapeutic approaches","volume":"2012","author":"Gavrilovskaya","year":"2012","journal-title":"Adv. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virusres.2013.12.036","article-title":"Hemorrhagic fever with renal syndrome in the new, and hantavirus pulmonary syndrome in the old world: Paradi(se)gm lost or regained?","volume":"187","author":"Clement","year":"2014","journal-title":"Virus Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM199404073301401","article-title":"Hantavirus pulmonary syndrome: A clinical description of 17 patients with a newly recognized disease. The hantavirus study group","volume":"330","author":"Duchin","year":"1994","journal-title":"N Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/00365549309008537","article-title":"Puumala virus infection without signs of renal involvement","volume":"25","author":"Alexeyev","year":"1993","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/CMR.00062-09","article-title":"A global perspective on hantavirus ecology, epidemiology, and disease","volume":"23","author":"Jonsson","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3201\/eid1608.090470","article-title":"Hantavirus infections in humans and animals, China","volume":"16","author":"Zhang","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3201\/eid1912.131217","article-title":"Twenty-year summary of surveillance for human hantavirus infections, United States","volume":"19","author":"Knust","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14745\/ccdr.v41i06a02","article-title":"Hantavirus pulmonary syndrome in canada: An overview of clinical features, diagnostics, epidemiology and prevention","volume":"41","author":"Drebot","year":"2015","journal-title":"Can. Commun Dis. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3201\/eid2104.141437","article-title":"Hantavirus pulmonary syndrome, Southern Chile, 1995-2012","volume":"21","author":"Riquelme","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/jmv.25446","article-title":"Epidemiological description, case-fatality rate, and trends of hantavirus pulmonary syndrome: 9 years of surveillance in Argentina","volume":"91","author":"Alonso","year":"2019","journal-title":"J. Med. Virol"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3201\/eid1612.091170","article-title":"Hantavirus pulmonary syndrome in Argentina, 1995-2008","volume":"16","author":"Martinez","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3201\/eid1504.080289","article-title":"Hantavirus pulmonary syndrome, Central Plateau, Southeastern, and Southern Brazil","volume":"15","author":"Figueiredo","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virusres.2014.01.015","article-title":"Hantaviruses and cardiopulmonary syndrome in South America","volume":"187","author":"Figueiredo","year":"2014","journal-title":"Virus Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/21645515.2016.1253645","article-title":"The assessment of hantaan virus-specific antibody responses after the immunization program for hemorrhagic fever with renal syndrome in Northwest China","volume":"13","author":"Li","year":"2017","journal-title":"Hum. Vaccin. Immunother"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0264-410X(99)00057-2","article-title":"Antibody responses in humans to an inactivated hantavirus vaccine (hantavax)","volume":"17","author":"Cho","year":"1999","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/infdis\/jiy037","article-title":"Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome","volume":"217","author":"Jung","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.vaccine.2016.01.031","article-title":"Long-term immunogenicity and safety of inactivated hantaan virus vaccine (hantavax) in healthy adults","volume":"34","author":"Song","year":"2016","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.23876\/j.krcp.18.0044","article-title":"Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome","volume":"37","author":"Yi","year":"2018","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3201\/eid0302.970202","article-title":"Hantaviruses: A global disease problem","volume":"3","author":"Schmaljohn","year":"1997","journal-title":"Emerg. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1128\/JVI.03118-13","article-title":"Hantavirus gn and gc glycoproteins self-assemble into virus-like particles","volume":"88","author":"Acuna","year":"2014","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-1702(95)00053-S","article-title":"Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of hantaan virus","volume":"38","author":"Betenbaugh","year":"1995","journal-title":"Virus Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63488","DOI":"10.18632\/oncotarget.11329","article-title":"Construction and immunological characterization of CD40L or GM-CSF incorporated hantaan virus like particle","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1099\/jmm.0.000897","article-title":"Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection","volume":"68","author":"Dong","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1099\/0022-1317-78-8-2049","article-title":"Mosaic hepatitis b virus core particles allow insertion of extended foreign protein segments","volume":"78","author":"Koletzki","year":"1997","journal-title":"J. Gen. Virol"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0264-410X(97)00172-2","article-title":"Chimaeric hbv core particles carrying a defined segment of puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model","volume":"16","author":"Ulrich","year":"1998","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-1656(99)00117-0","article-title":"New chimaeric hepatitis b virus core particles carrying hantavirus (serotype puumala) epitopes: Immunogenicity and protection against virus challenge","volume":"73","author":"Ulrich","year":"1999","journal-title":"J. Biotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1006\/viro.2000.0540","article-title":"Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis b virus core antigen influence b-cell immunogenicity and protective potential of core-derived particles","volume":"276","author":"Koletzki","year":"2000","journal-title":"Virology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1016\/j.vaccine.2005.02.025","article-title":"A hantavirus nucleocapsid protein segment exposed on hepatitis b virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies","volume":"23","author":"Geldmacher","year":"2005","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.virol.2004.02.022","article-title":"An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice","volume":"323","author":"Geldmacher","year":"2004","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/jvi.64.7.3162-3170.1990","article-title":"Antigenic subunits of hantaan virus expressed by baculovirus and vaccinia virus recombinants","volume":"64","author":"Schmaljohn","year":"1990","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/viro.1996.0075","article-title":"Characterization of puumala virus nucleocapsid protein: Identification of b-cell epitopes and domains involved in protective immunity","volume":"216","author":"Lundkvist","year":"1996","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1016\/S0264-410X(02)00341-9","article-title":"Yeast-expressed puumala hantavirus nucleocapsid protein induces protection in a bank vole model","volume":"20","author":"Dargeviciute","year":"2002","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1128\/JVI.76.13.6669-6677.2002","article-title":"Cross-protection against challenge with puumala virus after immunization with nucleocapsid proteins from different hantaviruses","volume":"76","author":"Padula","year":"2002","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/088282404322875511","article-title":"Yeast-expressed hantavirus dobrava nucleocapsid protein induces a strong, long-lasting, and highly cross-reactive immune response in mice","volume":"17","author":"Geldmacher","year":"2004","journal-title":"Viral Immunol"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000093454","article-title":"Truncated recombinant dobrava hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice","volume":"49","author":"Maes","year":"2006","journal-title":"Intervirology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/vim.2007.0059","article-title":"Truncated recombinant puumala virus nucleocapsid proteins protect mice against challenge in vivo","volume":"21","author":"Maes","year":"2008","journal-title":"Viral Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0264-410X(92)90412-D","article-title":"Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome","volume":"10","author":"Schmaljohn","year":"1992","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1128\/jvi.69.10.6417-6423.1995","article-title":"A vaccinia virus-vectored hantaan virus vaccine protects hamsters from challenge with hantaan and seoul viruses but not puumala virus","volume":"69","author":"Chu","year":"1995","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1096-9071(200001)60:1<77::AID-JMV13>3.0.CO;2-S","article-title":"Clinical evaluation of a vaccinia-vectored hantaan virus vaccine","volume":"60","author":"McClain","year":"2000","journal-title":"J. Med. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1128\/JVI.00373-09","article-title":"Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus","volume":"83","author":"Safronetz","year":"2009","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1016\/j.vaccine.2005.12.040","article-title":"A pseudotype vesicular stomatitis virus containing hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice","volume":"24","author":"Lee","year":"2006","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12781","DOI":"10.1128\/JVI.00794-11","article-title":"Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with andes virus","volume":"85","author":"Brown","year":"2011","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/v6020516","article-title":"Long-term single-dose efficacy of a vesicular stomatitis virus-based andes virus vaccine in Syrian Hamsters","volume":"6","author":"Prescott","year":"2014","journal-title":"Viruses"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.vaccine.2015.05.007","article-title":"Construction and evaluation of DNA vaccine encoding hantavirus glycoprotein n-terminal fused with lysosome-associated membrane protein","volume":"33","author":"Jiang","year":"2015","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.12.001","article-title":"Recombinant DNA vaccine of hantavirus gn and lamp1 induced long-term immune protection in mice","volume":"138","author":"Jiang","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2017.12.011","article-title":"Hantavirus gc induces long-term immune protection via lamp-targeting DNA vaccine strategy","volume":"150","author":"Jiang","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/viro.1999.9961","article-title":"Comparison of the protective efficacy of naked DNA, DNA-based sindbis replicon, and packaged sindbis replicon vectors expressing hantavirus structural genes in hamsters","volume":"263","author":"Kamrud","year":"1999","journal-title":"Virology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/viro.1998.9586","article-title":"DNA vaccination with hantavirus m segment elicits neutralizing antibodies and protects against seoul virus infection","volume":"255","author":"Hooper","year":"1999","journal-title":"Virology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1128\/JVI.75.18.8469-8477.2001","article-title":"DNA vaccination with the hantaan virus m gene protects hamsters against three of four hfrs hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys","volume":"75","author":"Hooper","year":"2001","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1128\/CVI.00546-12","article-title":"Construction and nonclinical testing of a puumala virus synthetic m gene-based DNA vaccine","volume":"20","author":"Brocato","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1128\/JVI.77.18.9894-9905.2003","article-title":"Active and passive vaccination against hantavirus pulmonary syndrome with andes virus M genome segment-based DNA vaccine","volume":"77","author":"Custer","year":"2003","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1016\/j.vaccine.2013.07.025","article-title":"A novel sin nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (hps) and hemorrhagic fever with renal syndrome (HFRS)","volume":"31","author":"Hooper","year":"2013","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.vaccine.2012.01.024","article-title":"A phase 1 clinical trial of hantaan virus and puumala virus m-segment DNA vaccines for hemorrhagic fever with renal syndrome","volume":"30","author":"Boudreau","year":"2012","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/1469-0691.12553","article-title":"A phase 1 clinical trial of hantaan virus and puumala virus m-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation","volume":"20 Suppl 5","author":"Hooper","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.26.4.476","article-title":"Synergistic antiviral effects of ribavirin and the c-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses","volume":"26","author":"Huggins","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/infdis\/153.3.489","article-title":"Ribavirin therapy for hantaan virus infection in suckling mice","volume":"153","author":"Huggins","year":"1986","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/v5112704","article-title":"Ribavirin protects syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to andes virus","volume":"5","author":"Ogg","year":"2013","journal-title":"Viruses"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Haddock, E., Feldmann, F., Ebihara, H., and Feldmann, H. (2011). In vitro and in vivo activity of ribavirin against andes virus infection. PloS ONE, 6.","DOI":"10.1371\/journal.pone.0023560"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/23744235.2017.1293841","article-title":"Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by puumala virus","volume":"49","author":"Malinin","year":"2017","journal-title":"Infect. Dis. (Lond)"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965359900400404","article-title":"Intravenous ribavirin for hantavirus pulmonary syndrome: Safety and tolerance during 1 year of open-label experience. Ribavirin study group","volume":"4","author":"Chapman","year":"1999","journal-title":"Antivir. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/425007","article-title":"Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in north america","volume":"39","author":"Mertz","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1292\/jvms.63.637","article-title":"Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon hantavirus","volume":"63","author":"Murphy","year":"2001","journal-title":"J. Vet. Med. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2008.02.003","article-title":"Synthesis of 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against hantavirus","volume":"79","author":"Chung","year":"2008","journal-title":"Antiviral Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1128\/JVI.02397-07","article-title":"Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor vegf, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability","volume":"82","author":"Gavrilovskaya","year":"2008","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/JVI.02319-10","article-title":"Vegfr2 and src kinase inhibitors suppress andes virus-induced endothelial cell permeability","volume":"85","author":"Gorbunova","year":"2011","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.1128\/JVI.01405-10","article-title":"Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of ve-cadherin","volume":"84","author":"Rollin","year":"2010","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sundstrom, K.B., Nguyen Hoang, A.T., Gupta, S., Ahlm, C., Svensson, M., and Klingstrom, J. (2016). Andes hantavirus-infection of a 3d human lung tissue model reveals a late peak in progeny virus production followed by increased levels of proinflammatory cytokines and vegf-a. PLOS ONE, 11.","DOI":"10.1371\/journal.pone.0149354"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fimmu.2015.00432","article-title":"Multiplex analysis of serum cytokines in humans with hantavirus pulmonary syndrome","volume":"6","author":"Morzunov","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2016.05.014","article-title":"Effect of vandetanib on andes virus survival in the hamster model of hantavirus pulmonary syndrome","volume":"132","author":"Bird","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_78","unstructured":"Brocato, R.L., and Hooper, J.W. Evaluation of candidate drugs targeting hantavirus pulmonary syndrome in the Syrian hamster\/Andes virus disease model, In preparation."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"839","DOI":"10.7326\/0003-4819-42-4-839","article-title":"Cortisone therapy of early epidemic hemorrhagic fever: A preliminary report","volume":"42","author":"Sayer","year":"1955","journal-title":"Ann. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Tapia, M., Mansilla, C., and Vera, J. (2000). Sindrome pulmonar por hantavirus: Experiencia clinica en diagnostico y tratamiento. Hospital Coyhaique-Chile. Rev. Chil. Infect., 258\u2013269.","DOI":"10.4067\/S0716-10182000000300010"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cit394","article-title":"High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in chile: A double-blind, randomized controlled clinical trial","volume":"57","author":"Vial","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1099\/0022-1317-70-3-615","article-title":"Characterization of hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies","volume":"70","author":"Arikawa","year":"1989","journal-title":"J. Gen. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0042-6822(86)90058-9","article-title":"Characterization of glycoproteins of viruses causing hemorrhagic fever with renal syndrome (HFRS) using monoclonal antibodies","volume":"151","author":"Dantas","year":"1986","journal-title":"Virology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/jvi.52.1.231-237.1984","article-title":"Antigenic differences between two viruses, isolated in Japan and Korea, that cause hemorrhagic fever with renal syndrome","volume":"52","author":"Yamanishi","year":"1984","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/viro.1996.0113","article-title":"Bacterial expression of neutralizing mouse monoclonal antibody fab fragments to hantaan virus","volume":"217","author":"Liang","year":"1996","journal-title":"Virology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF01309700","article-title":"Protective role of antigenic sites on the envelope protein of hantaan virus defined by monoclonal antibodies","volume":"126","author":"Arikawa","year":"1992","journal-title":"Arch. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Garrido, J.L., Prescott, J., Calvo, M., Bravo, F., Alvarez, R., Salas, A., Riquelme, R., Rioseco, M.L., Williamson, B.N., and Haddock, E. (2018). Two recombinant human monoclonal antibodies that protect against lethal andes hantavirus infection in vivo. Sci Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aat6420"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1099\/vir.0.82459-0","article-title":"Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by sin nombre virus in the deer mouse model","volume":"88","author":"Medina","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Brocato, R., Josleyn, M., Ballantyne, J., Vial, P., and Hooper, J.W. (2012). DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLOS ONE, 7.","DOI":"10.1371\/journal.pone.0035996"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2875","article-title":"A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by andes virus","volume":"20","author":"Vial","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Haese, N., Brocato, R.L., Henderson, T., Nilles, M.L., Kwilas, S.A., Josleyn, M.D., Hammerbeck, C.D., Schiltz, J., Royals, M., and Ballantyne, J. (2015). Antiviral biologic produced in DNA vaccine\/goose platform protects hamsters against hantavirus pulmonary syndrome when administered post-exposure. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003803"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.virol.2005.11.035","article-title":"Hantaan\/andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates","volume":"347","author":"Hooper","year":"2006","journal-title":"Virology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/JVI.01822-07","article-title":"Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with andes virus","volume":"82","author":"Hooper","year":"2008","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"264ra162","DOI":"10.1126\/scitranslmed.3010082","article-title":"DNA vaccine-derived human igg produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome","volume":"6","author":"Hooper","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/erv.12.15","article-title":"Vaccines for hantaviruses: Progress and issues","volume":"11","author":"Schmaljohn","year":"2012","journal-title":"Expert Rev. Vaccines"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/7\/610\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:29Z","timestamp":1760187749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/7\/610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":95,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["v11070610"],"URL":"https:\/\/doi.org\/10.3390\/v11070610","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]}}}